Pharmacological cardioversion of atrial fibrillation (Q45237037)

11 December 2017

1 reference

title

Pharmacological cardioversion of atrial fibrillation (English)

1 reference

11 December 2017

1 reference

1 reference

J R Ehrlich

1

1 reference

11 December 2017

S H Hohnloser

series ordinal

2

1 reference

11 December 2017

language of work or name

German

0 references

publication date

1 January 2005

1 reference

Clinical Research in Cardiology

11 December 2017

published in

1 reference

11 December 2017

volume

94

1 reference

11 December 2017

issue

1

1 reference

11 December 2017

page(s)

14-22

1 reference

https://scigraph.springernature.com/pub.10.1007/s00392-005-0166-9

11 December 2017

exact match

0 references

cites work

Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Effects of procainamide on electrical activity in thoracic veins and atria in canine model of sustained atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Clinical challenge. II. Management of recent onset atrial fibrillation. PAFIT-2 Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Does amlodipine increase cancer incidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Cellular electropharmacology of amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Atrial flutter in patients treated for atrial fibrillation with propafenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

New ideas about atrial fibrillation 50 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Atrial fibrillation: maintenance of sinus rhythm versus rate control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

A comparison of rate control and rhythm control in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00392-005-0166-9

Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness

21 January 2018

1 reference

12 December 2020

Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators

1 reference

12 December 2020

Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation

1 reference

12 December 2020

Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications

1 reference

12 December 2020

Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study

1 reference

12 December 2020

Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation

1 reference

12 December 2020

Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm

1 reference

12 December 2020

Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol

1 reference

12 December 2020

Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation

1 reference

12 December 2020

Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group

1 reference

12 December 2020

Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation

1 reference

12 December 2020

Molecular mechanisms of early electrical remodeling: transcriptional downregulation of ion channel subunits reduces I(Ca,L) and I(to) in rapid atrial pacing in rabbits

1 reference

12 December 2020

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators

1 reference

12 December 2020

Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators

1 reference

12 December 2020

Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation

1 reference

12 December 2020

Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination

1 reference

12 December 2020

Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation

1 reference

12 December 2020

Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation

1 reference

12 December 2020

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine

1 reference

12 December 2020

Effects of experimental heart failure on atrial cellular and ionic electrophysiology

1 reference

12 December 2020

Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial

1 reference

12 December 2020

10.1007/S00392-005-0166-9

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1001486655

0 references

1 reference